公开(公告)号：US11161897B2

公开(公告)日：2021-11-02

申请号：US16037340

申请日：2018-07-17

Applicant: Janssen Biotech, Inc.

Inventor： Chichi Huang ,  John Lee ,  Jill Mooney ,  Michael Naso

IPC: C07K16/28 ,  C07K16/46 ,  C07K14/735 ,  A61K39/395 ,  C07K16/18

Abstract: Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer.

公开(公告)号：US11096998B2

公开(公告)日：2021-08-24

申请号：US16323121

申请日：2017-09-11

Applicant: Janssen Biotech, Inc.

Inventor： Chen Ni Chin ,  John Lee ,  Timothy McCabe ,  Jill Mooney ,  Michael Naso ,  William Strohl

IPC: C07K16/00 ,  C07K16/46 ,  C07K16/28 ,  A61K39/00 ,  C12N15/82 ,  A61P35/00 ,  C07K14/525 ,  C07K14/705 ,  C07K14/75 ,  C07K14/78

Abstract: BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.

公开(公告)号：US20210040210A1

公开(公告)日：2021-02-11

申请号：US16937285

申请日：2020-07-23

Applicant: Janssen Biotech, Inc.

Inventor： Rajkumar Ganesan ,  John Lee ,  Jinquan Luo ,  Theresa McDevitt ,  Fei Shen ,  Degang Song ,  Raymond Brittingham ,  Sathyadevi Venkataramani ,  Sanjaya Singh ,  Yonghong Zhao ,  Fang Yi ,  Sherry Lynn La Porte

IPC: C07K16/28 ,  C07K16/34

Abstract: Embodiments of the present invention provide isolated proteins comprising antigen binding domains that bind kallikrein related peptidase 2 (hK2), including monospecific and bispecific antibodies. Additional embodiments of the invention provide polynucleotides encoding the hk2-specific proteins, vectors, host cells, and methods of making and using them.

公开(公告)号：US20200231686A1

公开(公告)日：2020-07-23

申请号：US16743188

申请日：2020-01-15

Applicant: Janssen Biotech, Inc.

Inventor： Ricardo Attar ,  Rajkumar Ganesan ,  Francois Gaudet ,  Bradley J. Heidrich ,  Carmen Baca Jones ,  John Lee ,  Yingzhe Li ,  Sanjaya Singh ,  Sathya Venkataramani

IPC: C07K16/28 ,  A61P35/00 ,  A61K9/00

Abstract: The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.

公开(公告)号：US20190330361A1

公开(公告)日：2019-10-31

申请号：US16323121

申请日：2017-09-11

Applicant: Janssen Biotech, Inc.

Inventor： Chen Ni Chin ,  John Lee ,  Timothy McCabe ,  Jill Mooney ,  Michael Naso ,  William Strohl

IPC: C07K16/28 ,  C12N15/82

Abstract: BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.

公开(公告)号：US20190175651A1

公开(公告)日：2019-06-13

申请号：US16215716

申请日：2018-12-11

Applicant: Janssen Biotech, Inc.

Inventor： John Lee ,  Jill Mooney ,  Michael Naso

IPC: A61K35/17 ,  C07K14/78 ,  C07K14/47 ,  C07K14/705 ,  C07K14/715 ,  A61P35/00 ,  C12N15/85 ,  C12N15/90

Abstract: The present invention pertains to engineered immortalized T-cell lines, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immortalized T-cell lines of the invention are characterized in that the expression of endogenous T-cell receptors (TCRs) and beta 2-microglobulin (B2M) is inhibited, e.g., by using an endonuclease able to selectively inactivate the TCR and B2M genes in order to render the immortalized T-cells non-alloreactive. In addition, expression of immunosuppressive polypeptide can be performed on those engineered immortalized T-cells in order to prolong the survival of these T-cells in host organisms. Such engineered immortalized T-cells are particularly suitable for allogeneic transplantations, especially because it reduces both the risk of rejection by the host's immune system and the risk of developing graft versus host disease. The invention opens the way to standard and affordable adoptive immunotherapy strategies using immortalized T-cells for treating cancer, infections and auto-immune diseases.

公开(公告)号：US12077592B2

公开(公告)日：2024-09-03

申请号：US16743188

申请日：2020-01-15

Applicant: Janssen Biotech, Inc.

Inventor： Ricardo Attar ,  Rajkumar Ganesan ,  Francois Gaudet ,  Bradley J. Heidrich ,  Carmen Baca Jones ,  John Lee ,  Yingzhe Li ,  Sanjaya Singh ,  Sathya Venkataramani

IPC: C07K16/28 ,  A61K9/00 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61K9/0019 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.

公开(公告)号：US20240124583A1

公开(公告)日：2024-04-18

申请号：US18397711

申请日：2023-12-27

Applicant: Janssen Biotech, Inc.

Inventor： Rajkumar Ganesan ,  John Lee ,  Jinquan Luo ,  Theresa McDevitt ,  Fei Shen ,  Degang Song ,  Raymond Brittingham ,  Sathyadevi Venkataramani ,  Sanjaya Singh ,  Yonghong Zhao ,  Fang Yi ,  Sherry Lynn LaPorte

IPC: C07K16/28 ,  C07K16/34

CPC classification number: C07K16/2809 ,  C07K16/34 ,  C07K2317/14 ,  C07K2317/31 ,  C07K2317/565

Abstract: Embodiments of the present invention provide isolated proteins comprising antigen binding domains that bind kallikrein related peptidase 2 (hK2), including monospecific and bispecific antibodies. Additional embodiments of the invention provide polynucleotides encoding the hk2-specific proteins, vectors, host cells, and methods of making and using them.

公开(公告)号：US12077585B2

公开(公告)日：2024-09-03

申请号：US16937285

申请日：2020-07-23

Applicant: Janssen Biotech, Inc.

Inventor： Rajkumar Ganesan ,  John Lee ,  Jinquan Luo ,  Theresa McDevitt ,  Fei Shen ,  Degang Song ,  Raymond Brittingham ,  Sathyadevi Venkataramani ,  Sanjaya Singh ,  Yonghong Zhao ,  Fang Yi ,  Sherry Lynn La Porte

IPC: C07K16/28 ,  C07K16/34

CPC classification number: C07K16/2809 ,  C07K16/34 ,  C07K2317/14 ,  C07K2317/31 ,  C07K2317/565

Abstract: Embodiments of the present invention provide isolated proteins comprising antigen binding domains that bind kallikrein related peptidase 2 (hK2), including monospecific and bispecific antibodies. Additional embodiments of the invention provide polynucleotides encoding the hk2-specific proteins, vectors, host cells, and methods of making and using them.

公开(公告)号：US20240262921A1

公开(公告)日：2024-08-08

申请号：US18643356

申请日：2024-04-23

Applicant: Janssen Biotech, Inc.

Inventor： Ricardo ATTAR ,  Rajkumar Ganesan ,  Francois Gaudet ,  Bradley J. Heidrich ,  Carmen Baca Jones ,  John Lee ,  Yingzhe Li ,  Sanjaya Singh ,  Sathya Venkataramani

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2866 ,  A61K9/0019 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.